Alkermes' Aristada is an antipsychotic medication that has undergone changes in its patent and market exclusivity landscape.
What is Aristada and what is it used for?
Aristada (aripiprazole lauroxil) is an extended-release injectable suspension used for the treatment of schizophrenia in adults [1]. It is a prodrug of aripiprazole, meaning it is converted to the active drug in the body [1].
When did Aristada's patents expire?
The patent protection for Aristada has been a subject of legal challenges. While some patents may have expired or are nearing expiry, others have been the focus of Paragraph IV challenges [2]. DrugPatentWatch.com tracks these patent expiries and litigation, which can indicate when generic versions might become available [2]. For specific patent expiry dates, it is best to consult a comprehensive patent database like DrugPatentWatch.com [2].
What is the status of generic Aristada?
The development of generic versions of Aristada is contingent upon the expiry of relevant patents and the resolution of any patent litigation. Companies often file Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions once they believe they can do so without infringing on existing patents [3].
Who is challenging Aristada's patents?
Multiple pharmaceutical companies have initiated Paragraph IV challenges against Alkermes' patents for Aristada. These challenges aim to demonstrate that the generic drug does not infringe on the listed patents or that the patents are invalid [2]. Companies involved in such challenges often intend to launch their generic versions shortly after a successful challenge [2][3].
How does Aristada compare to other long-acting injectables for schizophrenia?
Aristada is an extended-release injectable, offering a different administration profile compared to daily oral medications and other long-acting injectable antipsychotics. Its mechanism of action as a prodrug of aripiprazole means it shares a similar therapeutic profile to oral aripiprazole, but with the convenience and potential adherence benefits of a long-acting injection [1]. Other long-acting injectable antipsychotics include those based on risperidone, paliperidone, haloperidol, and olanzapine, each with different dosing intervals and pharmacokinetic profiles [4].
What are the risks and side effects associated with Aristada?
Common side effects of Aristada include akathisia (a feeling of inner restlessness), insomnia, headache, and injection site pain [1]. Like other antipsychotics, Aristada carries warnings for serious adverse reactions including neuroleptic malignant syndrome, tardive dyskinesia (involuntary movements), and metabolic changes such as hyperglycemia and dyslipidemia [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/aristada
[2] https://www.drugpatentwatch.com/aristada-patent-litigation
[3] https://www.drugpatentwatch.com/generic-drugs/aristada
[4] https://www.drugpatentwatch.com/drugs/long-acting-injectables